Analyzing Stock On Your Own: Arcutis Biotherapeutics Inc (NASDAQ: ARQT)

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) does about 3.78M shares in volume on a normal day but saw 2337389 shares change hands in Monday’s trading. The company now has a market cap of 923.08M USD. Its current market price is $7.99, marking an increase of 1.91% compared to the previous close of $7.84. The 52 week high reached by this stock is $13.17 whilst the lowest price level in 52 weeks is $1.76.

Arcutis Biotherapeutics Inc (ARQT) has a 20-day trading average at $8.63 and the current price is -39.33% off the 52-week high compared with 353.98% distance from its 52-week low. The 50-day simple moving average of the closing price is $9.77 and its 200-day simple moving average is $6.39. If we look at the stock’s price movements over the week, volatility stands at 6.23%, which increases to 7.35% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 38.35 to suggest the stock is neutral.

The consensus objective for the share price is $18.00, suggesting that the stock has a potential upside of 55.61% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 03, 2024 when Mizuho upgraded the stock to “Buy” and issued a price target of between $4 and $8. Mizuho downgraded the stock to “Neutral” from Buy on October 26, 2023 at a price target of $57-$4. Goldman downgraded its price target at $32-$6.

Arcutis Biotherapeutics Inc (ARQT) stock is up 0.50% over the week and -21.67% over the past month. Its price is 147.37% year-to-date and -26.22% over the past year.

The stock last released its quarterly earnings report for quarter ended 12/31/2023, with the company’s earnings per share (EPS) of -1.31 below consensus estimates by -0.03. The company’s next earnings report forecasts estimating quarterly EPS at -0.73 and -2.4 for whole year. Expected sales for next quarter are $24.14M, which analysts say will come at $115.74M for the current fiscal year and next year at $228.9M. In addition, estimates put the company’s current quarterly revenue at an average of $14.68M.

To reach the target analysts have set, the stock logically needs to grow 55.61 percent from here.

The beta has a value of 1.16. Price to book ratio is 8.72.